Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues

Charles Dai, Yoon Mi Chung, Evan Kovac, Ziqi Zhu, Jianneng Li, Cristina Magi-Galluzzi, Andrew J. Stephenson, Eric A. Klein, Nima Sharifi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5a-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, the metabolic pathway of adrenal-derived DHT biosynthesis has not been rigorously investigated in the setting of primary disease in the prostate. Experimental Design: Seventeen patients with clinically localized prostate cancer were consented for fresh tissues after radical prostatectomy. Prostate tissues were cultured ex vivo in media spiked with an equimolar mixture of AD and T, and stable isotopic tracing was employed to simultaneously follow the enzymatic conversion of both precursor steroids into nascent metabolites, detected by liquid chromatography-tandem mass spectrometry. CRPC cell line models and xenograft tissues were similarly assayed for comparative analysis. A tritium-labeled steroid radiotracing approach was used to validate our findings. Results: Prostatectomy tissues readily 5a-reduced both T and AD. Furthermore, 5a-reduction of AD was the major directionality of metabolic flux to DHT. However, AD and T were comparably metabolized by 5a-reductase in primary prostate tissues, contrasting the preference exhibited by CRPC in which AD was favored over T. 5a-reductase inhibitors effectively blocked the conversion of AD to DHT. Conclusions: Both AD and T are substrates of 5a-reductase in prostatectomy tissues, resulting in two distinctly nonredundant metabolic pathways to DHT. Furthermore, the transition to CRPC may coincide with a metabolic switch toward AD as the favored substrate.

Original languageEnglish (US)
Pages (from-to)6351-6363
Number of pages13
JournalClinical Cancer Research
Volume23
Issue number20
DOIs
StatePublished - Oct 15 2017

Fingerprint

Androstenedione
Dihydrotestosterone
Prostatectomy
Castration
Prostatic Neoplasms
Oxidoreductases
Prostate
Metabolic Networks and Pathways
Steroids
Tritium
Tandem Mass Spectrometry
Heterografts
Liquid Chromatography
Testosterone
Research Design
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. / Dai, Charles; Chung, Yoon Mi; Kovac, Evan; Zhu, Ziqi; Li, Jianneng; Magi-Galluzzi, Cristina; Stephenson, Andrew J.; Klein, Eric A.; Sharifi, Nima.

In: Clinical Cancer Research, Vol. 23, No. 20, 15.10.2017, p. 6351-6363.

Research output: Contribution to journalArticle

Dai, C, Chung, YM, Kovac, E, Zhu, Z, Li, J, Magi-Galluzzi, C, Stephenson, AJ, Klein, EA & Sharifi, N 2017, 'Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues', Clinical Cancer Research, vol. 23, no. 20, pp. 6351-6363. https://doi.org/10.1158/1078-0432.CCR-17-1313
Dai, Charles ; Chung, Yoon Mi ; Kovac, Evan ; Zhu, Ziqi ; Li, Jianneng ; Magi-Galluzzi, Cristina ; Stephenson, Andrew J. ; Klein, Eric A. ; Sharifi, Nima. / Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 20. pp. 6351-6363.
@article{d0cedd2423ea4bce8e82ecab7f1556b2,
title = "Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues",
abstract = "Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5a-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, the metabolic pathway of adrenal-derived DHT biosynthesis has not been rigorously investigated in the setting of primary disease in the prostate. Experimental Design: Seventeen patients with clinically localized prostate cancer were consented for fresh tissues after radical prostatectomy. Prostate tissues were cultured ex vivo in media spiked with an equimolar mixture of AD and T, and stable isotopic tracing was employed to simultaneously follow the enzymatic conversion of both precursor steroids into nascent metabolites, detected by liquid chromatography-tandem mass spectrometry. CRPC cell line models and xenograft tissues were similarly assayed for comparative analysis. A tritium-labeled steroid radiotracing approach was used to validate our findings. Results: Prostatectomy tissues readily 5a-reduced both T and AD. Furthermore, 5a-reduction of AD was the major directionality of metabolic flux to DHT. However, AD and T were comparably metabolized by 5a-reductase in primary prostate tissues, contrasting the preference exhibited by CRPC in which AD was favored over T. 5a-reductase inhibitors effectively blocked the conversion of AD to DHT. Conclusions: Both AD and T are substrates of 5a-reductase in prostatectomy tissues, resulting in two distinctly nonredundant metabolic pathways to DHT. Furthermore, the transition to CRPC may coincide with a metabolic switch toward AD as the favored substrate.",
author = "Charles Dai and Chung, {Yoon Mi} and Evan Kovac and Ziqi Zhu and Jianneng Li and Cristina Magi-Galluzzi and Stephenson, {Andrew J.} and Klein, {Eric A.} and Nima Sharifi",
year = "2017",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-17-1313",
language = "English (US)",
volume = "23",
pages = "6351--6363",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues

AU - Dai, Charles

AU - Chung, Yoon Mi

AU - Kovac, Evan

AU - Zhu, Ziqi

AU - Li, Jianneng

AU - Magi-Galluzzi, Cristina

AU - Stephenson, Andrew J.

AU - Klein, Eric A.

AU - Sharifi, Nima

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5a-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, the metabolic pathway of adrenal-derived DHT biosynthesis has not been rigorously investigated in the setting of primary disease in the prostate. Experimental Design: Seventeen patients with clinically localized prostate cancer were consented for fresh tissues after radical prostatectomy. Prostate tissues were cultured ex vivo in media spiked with an equimolar mixture of AD and T, and stable isotopic tracing was employed to simultaneously follow the enzymatic conversion of both precursor steroids into nascent metabolites, detected by liquid chromatography-tandem mass spectrometry. CRPC cell line models and xenograft tissues were similarly assayed for comparative analysis. A tritium-labeled steroid radiotracing approach was used to validate our findings. Results: Prostatectomy tissues readily 5a-reduced both T and AD. Furthermore, 5a-reduction of AD was the major directionality of metabolic flux to DHT. However, AD and T were comparably metabolized by 5a-reductase in primary prostate tissues, contrasting the preference exhibited by CRPC in which AD was favored over T. 5a-reductase inhibitors effectively blocked the conversion of AD to DHT. Conclusions: Both AD and T are substrates of 5a-reductase in prostatectomy tissues, resulting in two distinctly nonredundant metabolic pathways to DHT. Furthermore, the transition to CRPC may coincide with a metabolic switch toward AD as the favored substrate.

AB - Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5a-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, the metabolic pathway of adrenal-derived DHT biosynthesis has not been rigorously investigated in the setting of primary disease in the prostate. Experimental Design: Seventeen patients with clinically localized prostate cancer were consented for fresh tissues after radical prostatectomy. Prostate tissues were cultured ex vivo in media spiked with an equimolar mixture of AD and T, and stable isotopic tracing was employed to simultaneously follow the enzymatic conversion of both precursor steroids into nascent metabolites, detected by liquid chromatography-tandem mass spectrometry. CRPC cell line models and xenograft tissues were similarly assayed for comparative analysis. A tritium-labeled steroid radiotracing approach was used to validate our findings. Results: Prostatectomy tissues readily 5a-reduced both T and AD. Furthermore, 5a-reduction of AD was the major directionality of metabolic flux to DHT. However, AD and T were comparably metabolized by 5a-reductase in primary prostate tissues, contrasting the preference exhibited by CRPC in which AD was favored over T. 5a-reductase inhibitors effectively blocked the conversion of AD to DHT. Conclusions: Both AD and T are substrates of 5a-reductase in prostatectomy tissues, resulting in two distinctly nonredundant metabolic pathways to DHT. Furthermore, the transition to CRPC may coincide with a metabolic switch toward AD as the favored substrate.

UR - http://www.scopus.com/inward/record.url?scp=85028924070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028924070&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-1313

DO - 10.1158/1078-0432.CCR-17-1313

M3 - Article

VL - 23

SP - 6351

EP - 6363

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -